Merck Buys Into Orna's Circular RNA Platform With Emphasis On Vaccines

 
• By Jessica Merrill

Orna is retaining full ownership of its "crown jewel," in situ CAR programs for cancer. CEO Tom Barnes talked to Scrip about the deal and Orna's business strategy.

circles
Orna thinks circular RNA will present new drug therapeutics and vaccines • Source: Shutterstock

More from Deals

More from Business